- Contact Us
- News and Events
- Investor Relations
- Locations and Facilities
- Careers
- About Our Site
- Accessibility Statement
- Privacy Policy
- Terms and Conditions
- For Employers and Medical Plan Providers
- For Pharmacists and Medical Professionals
- Drug Lists
- Drug Safety Alerts
- Emergency Response
- Mail Service Numbers, Forms and Information
- Specialty Pharmacy Services, Information and Forms
- Electronic Prior Authorization Information
- Clinical Drug Information
- Clinical Programs and Health Management
- Clinical Publications
- FAQs For Pharmacists and Pharmacy Staff
- Pharmacy Help Desk
- FAQs For Prescribers and Office Staff
- Contact Us | Health Professionals Only
Drug Safety Alerts
Sunovian Product Discontinuation
3/19/2020
Sunovion’s licensing agreement with Novartis for Arcapta® Neohaler®, Utibron® Neohaler® and Seebri® Neohaler ends on March 31, 2020 and the products will no longer be available in the U.S.
Sunovion will cease shipping Arcapta Neohaler, Utibron Neohaler and Seebri Neohaler into the trade as of March 31, 2020. However, Sunovion will continue to fulfill its contract pricing obligations on transactions that occur after March 31, 2020. After this date, Sunovion anticipates there will be a limited supply available at pharmacies until their supply is depleted.
Sunovion recommends that health care providers speak with their patients to find an alternate medication to treat their condition.
For more information, health care providers may contact Sunovion at 1-888-394-7377 and select option 3 before April 1, 2020. After April 1, 2020, please contact Novartis at 1‑888-NOW-NOVA. You may also call the United States Food and Drug Administration (FDA) consumer inquiry line toll-free at 1‑888‑INFO-FDA (1‑888-463-6332).